Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems.
Where this comes from
- Record sourced from PubMed, PMID 1328538.
- Also identified by PMC identifier 1015097.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Vigabatrin is a specific gamma-aminobutyric acid transaminase inhibitor. The clinical use of this drug in the treatment of epilepsy has been sporadically linked to the development of psychosis. Using 123I-IBZM, a specific dopamine D2 receptor ligand and single photon emission tomography (SPET), one month of treatment with vigabatrin was associated with a decrease in specific binding of 123I-IBZM to D2 receptors in the left hemisphere basal ganglia. This change may provide one explanation for the development of psychosis in vulnerable patients.
Medical subject headings
- Aminocaproates
- Anticonvulsants
- Corpus Striatum
- Epilepsies, Myoclonic
- Epilepsy, Complex Partial
- Receptors, Dopamine
- Receptors, GABA-A